ReviewMolecular diagnosis & therapy2019
MicroRNAs: Key Players in Bladder Cancer.
Review in Molecular diagnosis & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis.BioMed research international · 2021Pooled it
- Trial
- Utilizing a novel mitochondrial-related gene signature for predicting the prognosis and immunological impact in bladder cancer.Discover oncology · 2025Article
- miR-145-Mediated Tumor Suppression in Bladder Urothelial Carcinoma via Targeting the ADAMTS5/Wnt Signaling Axis.Cureus · 2025Article
- Innovative logic "AND" gate gene circuits for bladder cancer treatment: preclinical study.International journal of surgery (London, England) · 2025Article
- Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy.Frontiers in oncology · 2025Review
- 2'-Hydroxyflavanone inhibits bladder cancer cell proliferation and angiogenesis via regulating miR-99a-5p/mTOR signaling.American journal of clinical and experimental urology · 2025Article
- ADAMTS16 Suppression by MicroRNA-25 Leads to Oncogenic Properties in Renal Cell Carcinoma.Combinatorial chemistry & high throughput screening · 2025Article
- Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.Journal of translational medicine · 2023Article
- miR-221-5p and miR-186-5p Are the Critical Bladder Cancer Derived Exosomal miRNAs in Natural Killer Cell Dysfunction.International journal of molecular sciences · 2022Article
- MicroRNA-186 suppresses cell proliferation and metastasis in bladder cancer.African health sciences · 2022Article
- Propofol modulates the proliferation, invasion and migration of bladder cancer cells through the miR‑145‑5p/TOP2A axis.Molecular medicine reports · 2021Article
- Exosomes in bladder cancer: novel biomarkers and targets.Journal of Zhejiang University. Science. B · 2021Article
- MiR-25 regulates cell proliferation and metastasis in bladder urothelial carcinoma.Journal of Cancer · 2021Article
- Identification and Validation of Hub Genes Associated with Bladder Cancer by Integrated Bioinformatics and Experimental Assays.Frontiers in oncology · 2021Article
- Non-Coding RNA m6A Modification in Cancer: Mechanisms and Therapeutic Targets.Frontiers in cell and developmental biology · 2021Review
- circCEP128 Knockdown Suppresses Bladder Cancer Progression via Regulating microRNA-515-5p/SDC1 Axis.Cancer management and research · 2021Article
- DNMT3B silencing suppresses migration and invasion by epigenetically promoting miR-34a in bladder cancer.Aging · 2020Article
- Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer.Cancers · 2020Article
- Role of tyrosine kinases in bladder cancer progression: an overview.Cell communication and signaling : CCS · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BC) is the second highest morbid malignancy of the urinary tract and the fifth most common cancer worldwide. BC is highly malignant with significant morbidity and mortality, especially muscle-invasive BC (MIBC), which has a poor prognosis and frequently recurs after the first resection. Therefore, more sensitive diagnostic tools and effective therapeutic methods are urgently needed. MicroRNAs (miRNAs) are small noncoding RNAs that regulate the expression of protein-coding genes by repressing their translation or cleaving RNA transcripts in a sequence-specific manner. miRNAs play very important roles in regulating genes related to tumorigenesis, tumor development, progression, metastasis and angiogenesis. With the rapid development of high-throughput sequencing technology, an increasing number of miRNAs with aberrant expression between either BC patients and healthy volunteers or between BC tumor tissues and matched peripheral control tissues have been recently examined. The tumor etiopathogenesis must be determined to promote the development of new markers as diagnostic and prognostic tools and targets for bladder tumor therapy, it is therefore vital to elucidate the function of miRNAs with aberrant expression in BC. In the present study, we examined the published data of BC-related miRNAs by reviewing their expression levels, possible functions, potential target genes, related molecular regulatory networks, candidate markers for prognosis and diagnosis, and prospective therapeutic cases, and we summarized the status of research on BC-related miRNAs in recent years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.